Modern aspects of diagnosis and treatment of cognitive impairments (literature review)
https://doi.org/10.14412/2074-2711-2023-1-83-89
Abstract
Cognitive impairments (CI) are among the most common types of neurological disorders that occur in the practice of both neurologists and doctors of other specialties. The article discusses the modern principles of CI classification according to severity, their clinical signs, diagnostic criteria, and the most important approaches to managing patients with dementia and non-dementia CI. A review of current publications on the treatment of mild CI syndrome (MIS) and dementia was carried out, it was shown that the treatment should be comprehensive and include nondrug methods (regular physical activity, cognitive training), correction of all vascular risk factors, as well as drug treatment aimed at improvement of cognitive functions. At the same time, the strategy for choosing drug therapy for CI is determined by the degree of their severity. The importance of early detection of CI is due to the fact that timely diagnosis of these disorders expands the potential for secondary prevention and therapeutic intervention, which can delay or even prevent the onset of professional and social maladjustment due to the development of dementia. The possibilities of modern neuroprotective and symptomatic therapy of CI, the place of akatinol memantine in the treatment of CI syndrome and dementia are shown. Modern data on the use of this drug in various nosological variants of diseases with MCI syndrome and dementia of varying severity are presented.
About the Authors
A. B. LokshinaRussian Federation
119021, Moscow, Rossolimo St., 11, Build. 1
Competing Interests:
The conflict of interest has not affected the results of the investigation.
V. V. Zakharov
Russian Federation
Vladimir Vladimirovich Zakharov
119021, Moscow, Rossolimo St., 11, Build. 1
Competing Interests:
The conflict of interest has not affected the results of the investigation.
N. V. Vakhnina
Russian Federation
119021, Moscow, Rossolimo St., 11, Build. 1
Competing Interests:
The conflict of interest has not affected the results of the investigation.
References
1. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. Lancet. 2017;390(10113):2673-734. doi:10.1016/S0140-6736(17)31363-6
2. Parfenov VA, Zaharov VV, Preobrazenskaya IS. Kognitivnyye rasstroystva [Cognitive impairment]. Moscow; 2014. 192 p. doi:10.1016/S0140-6736(17)31363-6 (In Russ.).
3. Yakhno NN, Zakharov VV, Lokshina AB, et al. Dementsii. Rukovodstvo dlya vrachey [Dementia. Guidance for doctors]. 3<sup>rd</sup> ed. Moscow: MEDpress-inform; 2011. P. 17-28. Available from: https://www.03book.ru/upload/iblock/987/415_Demencija_Jahno.pdf (accessed 09.03.2022) (In Russ.).
4. Parfenov VA. Alzheimer's disease: clinical management errors. Meditsinskiy sovet = Medical Council. 2020;19:23-8. doi:10.21518/2079-701X-2020-19-23-28 (In Russ.).
5. Lokshina AB, Grishina DA. Treatment of noncognitive neuropsychiatric disorders in Alzheimer's disease. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(6):132-8. doi:10.14412/2074-2711-2021-6-132-138 (In Russ.).
6. Yakhno NN, Zakharov VV, Koberskaya NN, et al. Premild (subjective and subtle) cognitive disorders. Nevrologicheskiy zhurnal. 2017;22(4):198-204. doi:10.18821/1560-9545-2017-22-4-198-204 (In Russ.).
7. Yakhno NN, Koberskaya NN, Zakharov VV, et al. The influence of age, comorbide cardiovascular and emotional factors on subtle cognitive decline in average, elderly and old age. Nevrologicheskiy zhurnal. 2018;23(6):309-15. doi:10.18821/1560-9545-2018-23-6-309-315 (In Russ.).
8. Yakhno NN, Koberskaya NN, Zakharov VV, et al. The influence of age, comorbide cardiovascular and emotional factors on subjective cognitive decline. Nevrologicheskiy zhurnal. 2018;23(4):184-9. doi:10.18821/1560-9545-2018-23-4-184-189 (In Russ.).
9. Yakhno NN, Lokshina AB, Zakharov VV, et al. Mild cognitive impairment in Russian population. Zhurnal nevrologii i psihiatrii imeni S.S. Korsakova. 2019;119(5):179-80. doi:10.17116/jnevro201911905S (In Russ.).
10. Lokshina AB, Zakharov VV, Grishina DA, et al. Heterogeneity of the mild cognitive impairment syndrome (specialized outpatient service data analysis). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2021;13(3):34-41. doi:10.14412/2074-2711-2021-3-34-41 (In Russ.).
11. Overton M, Pihlsgard M, Elmstahl S. Prevalence and Incidence of Mild Cognitive Impairment across Subtypes, Age, and Sex. Dement Geriatr Cogn Disord. 2019;47(4-6):219-32. doi:10.1159/000499763
12. Sachdev PS, Lipnicki DM, Kochan NA, et al. Cohort Studies of Memory in an International Consortium (COSMIC).The Prevalence of Mild Cognitive Impairment in Diverse Geographical and Ethnocultural Regions: The COSMIC Collaboration. PLoS One. 2015;10(11):e0142388. doi:10.1371/journal.pone.0142388
13. Petersen RC, Lopez O, Armstrong MJ, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126-35. doi:10.1212/WNL.0000000000004826
14. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Diseases. Fifth Edition (DSM-V). London; 2013. Available from: https://www.psychiatry.org/psychiatrists/practice/dsm
15. Dementia. Comprehensive Principles and Practice. Oxford University Press; 2014. P. 377-83, 432-48. doi:10.1093/med/9780199928453.001.0001
16. Dongping R, Xiong L, Muni T, et al. Prevalence of mild cognitive impairment and its subtypes in community-dwelling residents aged 65 years or older in Guangzhou, China. Arch Gerontol Geriatr. 2018 Mar-Apr;75:70-5. doi:10.1016/j.archger.2017.11.003. Epub 2017 Nov 20.
17. Roberts RO, Geda YE, Knopman DS, et al. The Mayo Clinic Study of Aging: design and sampling, participation, baseline measures and sample characteristics. Neuroepidemiology. 2008;30(1):58-69. doi:10.1159/000115751
18. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008 Mar 18;148(6):427-34. doi:10.7326/0003-4819-148-6-200803180-00005. Erratum in: Ann Intern Med. 2009 Aug 18;151(4):291-2.
19. Farias ST, Mungas D, Reed BR, et al. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66(9):1151-7. doi:10.1001/archneurol.2009.106
20. Dubois B, Feldman H, Jacova C, et al. Revising the definition of Alzheimer's disease: a new lexicon. Lancet Neurol. 2010;9(11):1118-27. doi:10.1016/S1474-4422(10)70223-4
21. Chiong W, Tolchin BD, Bonnie RJ, et al; Ethics, Law, and Humanities Committee (a joint committee of the AAN, ANA, and CNS). Decisions with Patients and Families Regarding Aducanumab in Alzheimer Disease, With Recommendations for Consent: AAN Position Statement. Neurology. 2021 Nov 17:10.1212/WNL.0000000000013053. doi:10.1212/WNL.0000000000013053. Epub ahead of print.
22. Decourt B, Boumelhem F, Pope ED 3rd, et al. Critical Appraisal of Amyloid Lowering Agents in AD. Curr Neurol Neurosci Rep. 2021 Jun 10;21(8):39. doi:10.1007/s11910-021-01125-y
23. Chalfont G, Milligan C, Simpson J. A mixed methods systematic review of multimodal non-pharmacological interventions to improve cognition for people with dementia. Dementia (London). 2020;19(4):1086-130. doi:10.1177/1471301218795289
24. Zhu Y, Zhong Q, Ji J, et al. Effects of Aerobic Dance on Cognition in Older Adults with Mild Cognitive Impairment: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 2020;74(2):679-90. doi:10.3233/JAD-190681
25. Ngandu T, Lehtisalo J, Solomon A, et al. A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet. 2015; 385(9984):2255-63. doi:10.1016/S0140-6736(15)60461-5
26. Peters R, Booth A, Rockwood K, et al. Combining modifiable risk factors and risk of dementia: a systematic review and metaanalysis. BMJ Open. 2019;9(1):e022846. doi:10.1136/bmjopen-2018-022846
27. Van den Brink AC, Brouwer-Brolsma EM, Berendsen AAM, van de Rest O. The Mediterranean, Dietary Approaches to Stop Hypertension (DASH), and Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) Diets Are Associated with Less Cognitive Decline and a Lower Risk of Alzheimer's Disease-A Review. Adv Nutr. 2019;10(6):1040-65. doi:10.1093/advances/nmz054
28. Woods B, Aguirre E, Spector AE, Orrell M. Cognitive stimulation to improve cognitive functioning in people with dementia. Cochrane Database Syst Rev. 2012;(2):CD005562. doi:10.1002/14651858.CD005562.pub2
29. Giuli C, Fattoretti P, Gagliardi C, et al. My Mind Project: the effects of cognitive training for elderly – the study protocol of a prospective randomized intervention study. Aging Clin Exp Res. 2017;(29):353-60. doi:10.1007/s40520-016-0570-1
30. Cocchiara RA, De Lucia F, Koci L, et al. Management of the early stage of Alzheimer's disease: a systematic review of literature over the past 10 years. Clin Ter. 2020;171(4):e357-e368. doi:10.7417/CT.2020.2239
31. Matsunaga S, Fujishiro H, Takechi H. Efficacy and safety of cholinesterase inhibitors for mild cognitive impairment: a systematic review and meta-analysis. J Alzheimers Dis. 2019;71(2):513-23. doi:10.3233/JAD-190546
32. Lokshina AB. Modern aspects of diagnosis and treatment of mild cognitive impairment. Rossiyskiy zhurnal geriatricheskoy meditsiny = Russian Journal of Geriatric Medicine. 2020;(3):199-204. doi:10.37586/2686-8636-3-2020-199-204 (In Russ.).
33. Odinak MM, Litvinenko IV, Yemelin AYu. An open-label comparative study aimed at evaluation of the effectiveness of memantine administered in the course of treatment of posttraumatic cognitive impairment. Nevrologicheskiy zhurnal. 2005;(6):32-7 (In Russ.).
34. Reisberg B, Doody R, Stöffler A, et al; Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003 Apr 3;348(14):1333-41. doi:10.1056/NEJMoa013128
35. Tariot PN, Farlow MR, Grossberg GT, et al; Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004 Jan 21;291(3):317-24. doi:10.1001/jama.291.3.317
36. Areosa SA, Sherriff F, McShane R. Memantine for dementia. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD003154. doi:10.1002/14651858.CD003154.pub4. Update in: Cochrane Database Syst Rev. 2006;(2):CD003154.
37. Peskind ER, Potkin SG, Pomara N, et al. Memantine treatment in mild to moderate Alzheimer disease: a 24-week randomized, controlled trial. Am J Geriatr Psychiatry. 2006 Aug;14(8):704-15. doi:10.1097/01.JGP.0000224350.82719.83
38. Takahashi-Ito K, Makino M, Okado K, Tomita T. Memantine inhibits β-amyloid aggregation and disassembles preformed β-amyloid aggregates. Biochem Biophys Res Commun. 2017 Nov 4;493(1):158-63. doi:10.1016/j.bbrc.2017.09.058. Epub 2017 Sep 14.
39. McShane R, Westby MJ, Roberts E, et al. Memantine for dementia. Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi:10.1002/14651858.CD003154.pub6
40. Kishi T, Matsunaga S, Iwata N. The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis. Neuropsychiatr Dis Treat. 2017;13:1909-28. doi:10.2147/NDT.S142839
41. Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer's Disease. Biomed Res Int. 2016;2016:2589276. doi:10.1155/2016/2589276
42. Kodis EJ, Choi S, Swanson E, et al. N-methyl-D-aspartate receptor-mediated calcium influx connects amyloid-β oligomers to ectopic neuronal cell cycle reentry in Alzheimer's disease. Alzheimers Dement. 2018 Oct;14(10):1302-12. doi:10.1016/j.jalz.2018.05.017
43. Ilhan Algin D, Dagli Atalay S, Ozkan S, et al. Memantine improves semantic memory in patients with amnestic mild cognitive impairment: A single-photon emission computed tomography study. J Int Med Res. 2017 Dec;45(6):2053-64. doi:10.1177/0300060517715166. Epub 2017 Jun 29.
44. Yahno NN, Preobrazhenskaya IS, Zakharov VV, Mkhitaryan EA. The effectiveness of memantine administration in patients with non-dementia cognitive impairment. The results of a multicenter clinical follow-up study. Rossiiskii nevrologicheskiy zhurnal. 2019;(3):37-44. doi:10.30629/2658-7947-2019-24-3-37-44 (In Russ.).
45. Uspenskaya OV, Yahno NN. The effect of memantine on the cognitive functions in patients with the amnestic type of mild cognitive impairment (clinical-psychological and neurochemical study). Nevrologicheskij zhurnal. 2009;14(3):37-40 (In Russ.).
46. Wilcock G, Möbius HJ, Stöffler A; MMM 500 group. A double-blind, placebocontrolled multicentre study of memantine in mild to moderate vascular dementia (MMM500). Int Clin Psychopharmacol. 2002 Nov;17(6):297-305. doi:10.1097/00004850-200211000-00005
47. Orgogozo JM, Rigaud AS, Stöffler A, et al. Efficacy and safety of memantine in patients with mild to moderate vascular dementia: a randomized, placebo-controlled trial (MMM 300). Stroke. 2002 Jul;33(7):1834-9. doi:10.1161/01.str.0000020094.08790.49
48. Emre M, Tsolaki M, Bonuccelli U, et al; 11018 Study Investigators. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2010 Oct;9(10):969-77. doi:10.1016/S1474-4422(10)70194-0
49. Stepkina DA, Zakharov VV. The effect of memantine on the cognitive functions of patients with Parkinson's disease. Nevrologicheskiy zhurnal. 2008;13(2):43-7 (In Russ.).
Review
For citations:
Lokshina AB, Zakharov VV, Vakhnina NV. Modern aspects of diagnosis and treatment of cognitive impairments (literature review). Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2023;15(1):83-89. (In Russ.) https://doi.org/10.14412/2074-2711-2023-1-83-89